Alkermes has shown more of the data that persuaded it to throw money at its narcolepsy program. The phase 1b readout suggests Alkermes’ ALKS 2680 can hold its own against Takeda’s rival prospect ...

Alkermes plc (Nasdaq: ALKS) today announced new data from the full narcolepsy type 1 (NT1) cohort of a phase 1b, proof-of-concept study evaluating ALKS 2680, the company's novel, investigational, oral ...

Analyst Uy Ear of Mizuho Securities maintained a Buy rating on Alkermes (ALKS – Research Report), retaining the price target of $35.00.

Robert W. Baird analyst Joel Beatty has maintained their bullish stance on ALKS stock, giving a Buy rating on June 4. Joel Beatty has given ...

Robert W. Baird raised the price target for the Alkermes plc (NASDAQ:ALKS) stock to “an Outperform”. The rating was released on March 19, 2024, according to finviz. The research report from JP Morgan ...

Select "Add to Compare" to begin comparing Stocks, ETFs, Mutual Funds and more.

Targeting hormonal therapy for endometrial cancer is opening up the potential to improve outcomes without overtreating in the ...

At Thursday night’s Wilmington City Council meeting, members voted in favor by a 6-1 margin in support of the Davids Drive Connector Path project.

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

The annual Business Courier Best Places to Work program recognizes Greater Cincinnati companies that rate highest for employee satisfaction. Meet the 75 finalists here. The Business Courier has named ...